In broad context: Wegovy (semaglutide) changed the market by pushing average weight loss into the mid-teens Zepbound (tirzepatide) pushed average Phase 3 weight loss above 20% retatrutide is now pushing topline late-stage obesity results toward 30% That does not make cross-trial comparisons perfect
High constitutive signaling of the ghrelin receptoridentification of a potent inverse agonist
To minimize the side effects, healthcare providers typically adopt a gradual dosage increase over a few weeks
Kirsten WJ, Hesselius GU
Alaska, Alabama, Arkansas, DC, Delaware, Kansas, Louisiana, Mississippi, North Dakota, New Mexico, Rhode Island, South Dakota, Vermont, West Virginia, and Wyoming are all excluded
Hoy en da es el frmaco que en faseII induce mayor reduccin de peso, con un 24% (28,5% en mujeres) tras 48semanas con una dosis semanal de 12mg55 (tabla 1), alcanzando importantes beneficios en el control de FRCV y en la reduccin de MASLD56 (fig